Avacopan for the Treatment of ANCA-Associated Vasculitis.
David R W Jayne, Peter A Merkel, Thomas J Schall...
https://pubmed.ncbi.nlm.nih.gov/33596356/Actively Recruiting
Led by Chiba University · Updated on 2025-05-04
160
Participants Needed
22
Research Sites
78 weeks
Total Duration
Researchers are investigating the treatment of newly diagnosed ANCA-associated vasculitis, a serious condition affecting small- to medium-sized blood vessels. This phase 4 trial compares the effectiveness and safety of avacopan combined with short-term reduced-dose glucocorticoids and rituximab versus a longer course of reduced-dose glucocorticoids with rituximab. The study aims to understand if avacopan can achieve similar remission rates and reduce relapse compared to current therapies, while also assessing long-term safety. Participants will be randomly assigned to one of two treatment groups. One group receives avacopan daily along with a 4-week reduced-dose prednisolone course and rituximab infusions. The other group receives reduced-dose prednisolone tapered over 20 weeks plus rituximab infusions at scheduled times. Both groups have options for short-term rescue prednisolone if needed. Maintenance therapy continues with either avacopan or rituximab at regular intervals up to 24 months. Throughout the 104-week study, participants will be evaluated at multiple timepoints for disease activity, remission status, relapse, organ damage, and any adverse events. Assessments include standardized vasculitis activity scores and damage indices, quality of life questionnaires, and monitoring for side effects such as infections and new medical conditions. The main outcome measured is the proportion of patients achieving remission at 26 weeks, with ongoing follow-up to observe relapse rates and long-term safety.
CONDITIONS
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
S
Shunsuke Furuta, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Chiba University
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 26 weeks
Participants receive one of two drug regimens to induce remission of ANCA-associated vasculitis: either avacopan combined with short-term reduced-dose prednisolone and rituximab, or reduced-dose prednisolone and rituximab. The treatment includes rituximab infusions and glucocorticoid dosing as per group assignment.
Weekly rituximab infusions for 4 weeks plus regular visits for glucocorticoid tapering and avacopan dosing as applicable
Duration - 78 weeks
Participants are monitored for disease relapse, long-term safety, and remission maintenance. During this phase, participants receive maintenance therapy with rituximab or avacopan depending on their treatment group. Rescue prednisolone may be administered for minor relapse if needed.
Visits every 6 months for maintenance rituximab or daily avacopan intake with additional visits as needed for relapse monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
David R W Jayne, Peter A Merkel, Thomas J Schall...
https://pubmed.ncbi.nlm.nih.gov/33596356/Shunsuke Furuta, Daiki Nakagomi, Yoshihisa Kobayashi...
https://pubmed.ncbi.nlm.nih.gov/34061144/A R Exley, P A Bacon, R A Luqmani...
https://pubmed.ncbi.nlm.nih.gov/9041949/Joanna C Robson, Peter C Grayson, Cristina Ponte...
https://pubmed.ncbi.nlm.nih.gov/35110333/Ravi Suppiah, Joanna C Robson, Peter C Grayson...
https://pubmed.ncbi.nlm.nih.gov/35110332/J C Jennette, R J Falk, P A Bacon...
https://pubmed.ncbi.nlm.nih.gov/23045170/C Mukhtyar, R Lee, D Brown...
https://pubmed.ncbi.nlm.nih.gov/19054820/Bernhard Hellmich, Beatriz Sanchez-Alamo, Jan H Schirmer...
https://pubmed.ncbi.nlm.nih.gov/36927642/Chiba University
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Collaborating Sponsor